Breaking News Instant updates and real-time market news.

GILD

Gilead

$79.12

1.26 (1.62%)

, GSK

GlaxoSmithKline

$43.13

0.23 (0.54%)

08:46
10/03/16
10/03
08:46
10/03/16
08:46

Gilead HIV franchise could see risk from competitor data, says RBC Capital

RBC Capital analyst Michael Yee said his conversations with doctors leads him to think two dolutegravir HIV "doublet" studies being conducted by GlaxoSmithKline (GSK) and ViiV Healthcare - Glaxo's joint venture with Pfizer (PFE) and Shionogi - are likely to work and present an underappreciated risk to Gilead's (GILD) HIV franchise. Talks with investors lead Yee to believe few are even aware of this risk and that the consensus view is underestimating the probability these non-inferiority trials will work. Arguing that the consensus view should factor in more conservative assumptions for Gilead's HIV business post 2018 due to this risk, Yee cut his price target on Gilead to $95 from $105, but keeps an Outperform rating on the shares.

GILD

Gilead

$79.12

1.26 (1.62%)

GSK

GlaxoSmithKline

$43.13

0.23 (0.54%)

  • 06

    Nov

  • 11

    Nov

GILD Gilead
$79.12

1.26 (1.62%)

09/22/16
JANY
09/22/16
NO CHANGE
Target $64
JANY
Buy
Galapagos drug more important to Gilead after trial halt, says Janney Capital
Janney Capital analyst Debjit Chattopadhyay said Gilead Sciences' (GILD) termination of its combined Phase 2/3 study of GS-5745 in ulcerative colitis implies that Galapagos (GLPG) filgotinib is now potentially more important to Gilead's growth prospects. The analyst, who thinks upcoming data could provide meaningful upside for Galapagos shares even after the stock's 25% move up over the past three weeks, keeps a Buy rating and $64 fair value estimate on the stock.
09/27/16
LEER
09/27/16
DOWNGRADE
Target $94
LEER
Market Perform
Gilead downgraded to Market Perform from Outperform at Leerink
Leerink analyst Geoffrey Porges downgraded Gilead Sciences to Market Perform from Outperform and lowered his price target for the shares to $94 from $112. The biotech closed yesterday down 75c to $80.62. The analyst says he's now "outright bearish" on the company's Hepatitis C virus business. Gilead's HCV revenues will "decline faster, and farther," than the current consensus estimates forecast, Porges tells investors in a research note.
09/27/16
09/27/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Gilead (GILD) downgraded to Market Perform from Outperform at Leerink with analyst Geoffrey Porges saying he's now "outright bearish" on the company's Hepatitis C virus business. 2. J.M. Smucker (SJM) downgraded to Neutral from Outperform at Credit Suisse with analyst Robert Moskow saying that while the company raised its cost savings target as expected, he underestimated the hit to sales from difficult comparisons. 3. Discovery (DISCA) and Scripps Networks (SNI) downgraded to Sell from Neutral at MoffettNathanson. 4. Carter's (CRI) downgraded to Market Perform from Outperform at Wells Fargo with analyst Ike Boruchow saying his quarter-to-date store checks indicate "choppy" retail traffic trends and "deeper" pricing/promotional pressure. 5. Dollar Tree (DLTR) downgraded to Underweight from Neutral at Atlantic Equities with analyst Sam Hudson saying the second half comp inflection expected by consensus is "too demanding" and he expects multiple contraction if Family Dollar does not turn around. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
GSK GlaxoSmithKline
$43.13

0.23 (0.54%)

08/29/16
PIPR
08/29/16
NO CHANGE
PIPR
Overweight
Gilead risk from possible 2-drug HIV regimens 'nothing new,' says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said he has received a number of questions regarding a Wall Street Journal article highlighting a potential 2-drug HIV regimen based on GlaxoSmithKline's (GSK) dolutegravir, stating in response that 2-drug options looking to replace the 3-drug standard "have come and gone without success." Though there is "always the chance that a new 2-drug combo will thread the needle," Schimmer said he still strongly doubts the field will "rush to a novel paradigm any time soon" as he believes the advantage of a 2-drug over a 3-drug regimen is minimal. Gilead (GILD) is doing a "very good job converting it's HIV Viread-based regimens to TAF based ones" and should remain the leader in the HIV space when it can also offer an unboosted integrase inhibitor, said Schimmer, who keeps an Overweight rating on the stock.
09/13/16
EXAN
09/13/16
DOWNGRADE
EXAN
Underperform
GlaxoSmithKline downgraded to Underperform from Neutral at Exane BNP Paribas
09/23/16
PIPR
09/23/16
INITIATION
PIPR
Overweight
GlaxoSmithKline initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Richard Purkiss started GlaxoSmithKline with an Overweight rating and GBP 20 price target. The company's growth is defensive and its risks are declining, Purkiss tells investors in a research note.
09/23/16
09/23/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Morgan Stanley analyst Brian Nowak initiated Activision Blizzard (ATVI) and Electronic Arts (EA), both with Overweight ratings. The analyst is bullish on the digital gaming shift away from "units sold" to a business model based on users, engagement, and digital monetization. He sees digital in-game offerings resulting in recurring and growth user bases, increased per-game engagement, and further monetization opportunities. 2. AstraZeneca (AZN) and GlaxoSmithKline (GSK) both initiated with Overweight ratings by Piper Jaffray analyst Richard Purkiss. 3. Achillion (ACHN) initiated with an Outperform by Wedbush analyst Heather Behanna, who set a $13 price target on the shares. 4. Sysco (SYY) initiated with an Underweight at Barclays and $48 price target by analyst Karen Short. 5. Five Below (FIVE), Dollar Tree (DLTR) and Dollar General (DG) all initiated with Equal Weight ratings by Barclays analyst Karen Short. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

09:00
01/23/18
01/23
09:00
01/23/18
09:00
General news
U.S. equities are relatively subdued »

U.S. equities are…

FQVLF

First Quantum Minerals

$15.30

-0.01 (-0.07%)

08:59
01/23/18
01/23
08:59
01/23/18
08:59
Downgrade
First Quantum Minerals rating change  »

First Quantum Minerals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$53.46

1.55 (2.99%)

08:59
01/23/18
01/23
08:59
01/23/18
08:59
Hot Stocks
Verizon says not considering large media acquisition »

Says remaining a partner…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

SANM

Sanmina

$27.08

-8.35 (-23.57%)

08:59
01/23/18
01/23
08:59
01/23/18
08:59
Recommendations
Sanmina analyst commentary  »

Sanmina price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

JMBA

Jamba

08:59
01/23/18
01/23
08:59
01/23/18
08:59
Technical Analysis
Technical Take: Jamba down sharply on 2.1M share Block Trade »

The stock was last at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

TWTR

Twitter

$23.34

-0.31 (-1.31%)

08:57
01/23/18
01/23
08:57
01/23/18
08:57
Hot Stocks
Twitter COO Anthony Noto resigns to accept CEO role at other company »

Twitter announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

08:57
01/23/18
01/23
08:57
01/23/18
08:57
General news
Redbook Store Sales data reported »

Week of 1/20 Redbook…

SANM

Sanmina

$27.10

-8.35 (-23.55%)

08:56
01/23/18
01/23
08:56
01/23/18
08:56
Recommendations
Sanmina analyst commentary  »

Sanmina price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

WWD

Woodward

$81.02

0.52 (0.65%)

08:56
01/23/18
01/23
08:56
01/23/18
08:56
Initiation
Woodward initiated  »

Woodward re-initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

TWTR

Twitter

$23.32

-0.34 (-1.44%)

08:55
01/23/18
01/23
08:55
01/23/18
08:55
Hot Stocks
Breaking Hot Stocks news story on Twitter »

Twitter announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

GE

General Electric

$16.17

-0.09 (-0.55%)

, NFLX

Netflix

$227.58

7.12 (3.23%)

08:55
01/23/18
01/23
08:55
01/23/18
08:55
Options
Notable open interest changes for January 23rd »

Monday's total…

GE

General Electric

$16.17

-0.09 (-0.55%)

NFLX

Netflix

$227.58

7.12 (3.23%)

AAPL

Apple

$177.00

-1.46 (-0.82%)

BAC

Bank of America

$31.94

0.22 (0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

  • 30

    Jan

  • 01

    Feb

  • 15

    Feb

JMBA

Jamba

$9.14

-0.01 (-0.11%)

08:54
01/23/18
01/23
08:54
01/23/18
08:54
Syndicate
Jamba 2.1M share Block Trade priced at $8.25 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

ANET

Arista Networks

$275.68

4.84 (1.79%)

08:54
01/23/18
01/23
08:54
01/23/18
08:54
Recommendations
Arista Networks analyst commentary  »

Arista Networks price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

  • 21

    Feb

  • 26

    Feb

  • 13

    Mar

  • 14

    Mar

FSLR

First Solar

$68.96

-1.07 (-1.53%)

, TSLA

Tesla

$351.56

1.54 (0.44%)

08:53
01/23/18
01/23
08:53
01/23/18
08:53
Recommendations
First Solar, Tesla, JinkoSolar, JA Solar, Sunrun, Vivint Solar analyst commentary  »

30% solar import tariff…

FSLR

First Solar

$68.96

-1.07 (-1.53%)

TSLA

Tesla

$351.56

1.54 (0.44%)

JKS

JinkoSolar

$23.37

-0.8 (-3.31%)

JASO

JA Solar

$7.46

-0.01 (-0.13%)

RUN

Sunrun

$6.04

0.1 (1.68%)

VSLR

Vivint Solar

$3.55

-0.15 (-4.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$53.46

1.55 (2.99%)

08:52
01/23/18
01/23
08:52
01/23/18
08:52
Hot Stocks
Breaking Hot Stocks news story on Verizon »

Verizon says integration…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

JWN

Nordstrom

$52.82

0.82 (1.58%)

08:52
01/23/18
01/23
08:52
01/23/18
08:52
Downgrade
Nordstrom rating change  »

William Blair downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LITE

Lumentum

$45.20

-3.65 (-7.47%)

08:51
01/23/18
01/23
08:51
01/23/18
08:51
Recommendations
Lumentum analyst commentary  »

Lumentum price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

NDAQ

Nasdaq

$80.63

0.56 (0.70%)

, CBOE

Cboe Global Markets

$134.56

0.68 (0.51%)

08:49
01/23/18
01/23
08:49
01/23/18
08:49
Periodicals
Nasdaq assessing bitcoin futures that are different to rivals, CNBC reports »

Nasdaq (NDAQ) is…

NDAQ

Nasdaq

$80.63

0.56 (0.70%)

CBOE

Cboe Global Markets

$134.56

0.68 (0.51%)

CME

CME Group

$155.45

1.17 (0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 01

    Feb

  • 09

    Feb

LOGI

Logitech

$37.58

0.25 (0.67%)

08:49
01/23/18
01/23
08:49
01/23/18
08:49
Technical Analysis
Technical Take: Logitech up sharply after results beat consensus, FY18 view »

The stock was last at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

RMD

ResMed

$87.51

-1.17 (-1.32%)

08:49
01/23/18
01/23
08:49
01/23/18
08:49
Upgrade
ResMed rating change  »

ResMed upgraded to Market…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GGAL

Grupo Financiero

$69.79

-2.27 (-3.15%)

08:48
01/23/18
01/23
08:48
01/23/18
08:48
Initiation
Grupo Financiero initiated  »

Grupo Financiero…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$53.46

1.55 (2.99%)

08:48
01/23/18
01/23
08:48
01/23/18
08:48
Hot Stocks
Verizon says seeing elongation of upgrade cycle »

Says customers keeping…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

TRV

Travelers

$139.35

1.5 (1.09%)

08:47
01/23/18
01/23
08:47
01/23/18
08:47
Technical Analysis
Technical Take: Travelers trades at new high after earnings beat »

The shares were last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

JNJ

Johnson & Johnson

$148.14

0.78 (0.53%)

08:46
01/23/18
01/23
08:46
01/23/18
08:46
Hot Stocks
Johnson & Johnson 'very pleased' with launch of Tremfya »

Johnson & Johnson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 16

    Feb

  • 08

    Mar

CREE

Cree

$36.69

0.4 (1.10%)

08:46
01/23/18
01/23
08:46
01/23/18
08:46
Downgrade
Cree rating change  »

Cree downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.